
Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC
September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa
Updated on: October 11,2023
205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC
September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa
Updated on:October 11,2023
205
